Signaling Pathways Governing Glioma Cancer Stem Cells Behavior
Overview
Authors
Affiliations
Glioma is the most common malignant brain tumor that develops in the glial tissue. Several studies have identified that glioma cancer stem cells (GCSCs) play important roles in tumor-initiating features in malignant gliomas. GCSCs are a small population in the brain that presents an essential role in the metastasis of glioma cells to other organs. These cells can self-renew and differentiate, which are thought to be involved in the pathogenesis of glioma. Therefore, targeting GCSCs might be a novel strategy for the treatment of glioma. Accumulating evidence revealed that several signaling pathways, including Notch, TGF-β, Wnt, STAT3, AKT, and EGFR mediated GCSC growth, proliferation, migration, and invasion. Besides, non-coding RNAs (ncRNAs), including miRNAs, circular RNAs, and long ncRNAs have been found to play pivotal roles in the regulation of GCSC pathogenesis and drug resistance. Therefore, targeting these pathways could open a new avenue for glioma management. In this review, we summarized critical signaling pathways involved in the stimulation or prevention of GCSCs tumorigenesis and invasiveness.
Radiogenomics and machine learning predict oncogenic signaling pathways in glioblastoma.
Ahanger A, Aalam S, Masoodi T, Shah A, Khan M, Bhat A J Transl Med. 2025; 23(1):121.
PMID: 39871351 PMC: 11773707. DOI: 10.1186/s12967-025-06101-5.
Decoding the Role of Kinesin Superfamily Proteins in Glioma Progression.
Saadh M, Ghnim Z, Mahdi M, Chandra M, Ballal S, Bareja L J Mol Neurosci. 2025; 75(1):10.
PMID: 39847238 DOI: 10.1007/s12031-025-02308-9.
Unlocking the Potential of Circulating miRNAs as Biomarkers in Glioblastoma.
Suvarnapathaki S, Serrano-Farias A, Dudley J, Bettegowda C, Rincon-Torroella J Life (Basel). 2024; 14(10).
PMID: 39459612 PMC: 11509808. DOI: 10.3390/life14101312.
Hasan S, Mahmud Z, Hossain M, Islam S Mol Biol Rep. 2024; 51(1):1069.
PMID: 39424705 DOI: 10.1007/s11033-024-09996-3.
Wang H, Yao L, Chen J, Li Y, Su Z, Liu Y J Exp Clin Cancer Res. 2024; 43(1):252.
PMID: 39227950 PMC: 11373117. DOI: 10.1186/s13046-024-03175-9.